Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?
Colorectal cancer (CRC) is the second leading cause of cancer death in the world. Immunotherapy using monoclonal antibodies, immune-checkpoint inhibitors, adoptive cell therapy, and cancer vaccines has raised great hopes for treating poor prognosis metastatic CRCs that are resistant to the conventio...
Guardado en:
Autores principales: | Li-Feng Hu, Huan-Rong Lan, Dong Huang, Xue-Min Li, Ke-Tao Jin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/651160a5315c4b32923bdb3a175e02ed |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Personalized immunotherapy in cancer precision medicine
por: Kazuma Kiyotani, et al.
Publicado: (2021) -
A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma
por: Alexandre Harari, et al.
Publicado: (2021) -
Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer
por: Rui He, et al.
Publicado: (2021) -
LYMPHOCYTE SUBPOPULATIONS IN GASTRIC AND COLORECTAL CANCER PATIENTS AFTER IMMUNOTHERAPY WITH ACTIVATED LYMPHOCYTES
por: E. V. Abakushina, et al.
Publicado: (2014) -
EFFECT OF ANTIGEN-PRIMED DENDRITIC CELL-BASED IMMUNOTHERAPY ON ANTITUMOR CELLULAR IMMUNE RESPONSE IN PATIENTS WITH COLORECTAL CANCER
por: V. V. Kurilin, et al.
Publicado: (2021)